Romiplostim

Douglas B. Cines; Uma Yasothan; Peter Kirkpatrick

doi:10.1038/nrd2741

journal article Nov 01, 2008

Romiplostim

Douglas B. Cines

Uma Yasothan Peter Kirkpatrick

Nature Reviews Drug Discovery Vol. 7 No. 11 pp. 887-888 · Springer Science and Business Media LLC

View at Publisher Save 10.1038/nrd2741

Topics

No keywords indexed for this article. Browse by subject →

References

18

[1]

Cines, D. B. & Blanchette, V. S. Immune thrombocytopenic purpura. N. Engl. J. Med. 346, 995–1008 (2002). 10.1056/nejmra010501

[2]

Ballem, P. J. et al. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J. Clin. Invest. 80, 33–40 (1987). 10.1172/jci113060

[3]

Kaushansky, K. Historical review: megakaryopoiesis and thrombopoiesis. Blood 111, 981–986 (2008). 10.1182/blood-2007-05-088500

[4]

Nomura, S. et al. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 100, 728–730 (2002). 10.1182/blood.v100.2.728

[5]

Li, J. et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98, 3241–3248 (2001). 10.1182/blood.v98.12.3241

[6]

Broudy, V. C. & Lin, N. L. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine 25, 52–60 (2004). 10.1016/j.cyto.2003.05.001

[7]

Food and Drug Administration. FDA labelling information. FDA web site [online] , (2008).

[8]

Wang, B. et al. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin. Pharmacol. Ther. 76, 628–638 (2004). 10.1016/j.clpt.2004.08.010

[9]

Bussel, J. B. et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N. Engl. J. Med. 355, 1672–1681 (2006). 10.1056/nejmoa054626

[10]

Kuter, D. J. et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 371, 395–403 (2008). 10.1016/s0140-6736(08)60203-2

[11]

Cooper N. et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br. J. Haematol. 125, 232–239 (2004). 10.1111/j.1365-2141.2004.04889.x

[12]

Godeau, B. et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood 112, 999–1004 (2008). 10.1182/blood-2008-01-131029

[13]

Cohen, Y. C. et al. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch. Int. Med. 160, 1630–1638 (2000). 10.1001/archinte.160.11.1630

[14]

Bussel, J. B. et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N. Engl. J. Med. 357, 2237–2247 (2007). 10.1056/nejmoa073275

[15]

McHutchison, J. G. et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N. Engl. J. Med. 357, 2227–2236 (2007). 10.1056/nejmoa073255

[16]

Holley, B. et al. Oppenheimer Equity Research Report (Oppenheimer, 25 Aug 2008). 10.1162/wopj.2008.25.3.211

[17]

IMS MIDAS (2007).

[18]

To, A. Amgen (Natixis Bleichroeder, 06 March 2008).

Cited By

41

Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR

Takuo Suzuki, Akiko Ishii-Watabe · 2010

The Journal of Immunology

Metrics